Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) shares rose 7% in afternoon trading after the company received US regulatory approval to expand the use of its lung imaging agent, XENOVIEW, to children as young as six.
The decision by the Food and Drug Administration lowers the age threshold from 12, potentially opening access to around one million additional patients.
XENOVIEW, used in MRI scans to measure lung ventilation without radiation, will now be available for younger patients with chronic respiratory conditions.
Polarean will also roll out new dose delivery bags tailored to paediatric use, along with updated equipment to ensure accurate gas measurements for smaller lungs.
The company said the move marks a significant step in broadening access to advanced lung imaging, while also improving the technology’s appeal to hospitals.
A targeted launch of the paediatric system will begin later this year, starting with Cincinnati Children’s Hospital.
The stock rose 0.085p to 1.36p.